Products

HYDROS Handpiece
PROCEPT BioRobotics
Surgical AI
The HYDROS Handpiece is a single-use component of Procept Biorobotics' HYDROS Robotic System, an AI-powered surgical platform for Aquablation therapy, treating benign prostatic hyperplasia (BPH) with precision and heat-free waterjet resection.
HYDROS TRUS Probe
PROCEPT BioRobotics
Radiology & Imaging AI
The HYDROS Robotic System is the next-generation, AI-powered platform for Aquablation therapy, offering a minimally invasive, robotic-assisted waterjet treatment for benign prostatic hyperplasia (BPH) that aims to provide durable symptom relief while preserving sexual function and continence.
HYDROS Robotic System
PROCEPT BioRobotics
Surgical AI
The HYDROS Robotic System by Procept Biorobotics is an AI-powered surgical robot for Aquablation therapy, treating benign prostatic hyperplasia (BPH) with advanced image guidance and robotic precision to preserve sexual function and continence.

See all 3 products →

About Procept Biorobotics

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company commercializes Aquablation therapy through its AQUABEAM robotic platform, which is designed for the treatment of benign prostatic hyperplasia (BPH), a common enlargement of the prostate that can cause lower urinary tract symptoms. Aquablation therapy is a minimally invasive surgical procedure that utilizes a robotically controlled waterjet and real-time imaging to remove prostate tissue in a heat-free manner. This approach aims to provide predictable and reproducible outcomes, independent of prostate size or surgeon experience, while preserving sexual function and continence.

For physicians, PROCEPT BioRobotics’ technology offers a precise and personalized treatment option for BPH. The AQUABEAM Robotic System combines real-time ultrasound imaging with automated robotics, allowing surgeons to create a personalized treatment plan tailored to each patient’s unique anatomy. This enables targeted removal of prostate tissue while preserving critical structures that control erectile function, ejaculatory function, and continence. The HYDROS Robotic System, an AI-powered robotic technology, also delivers Aquablation therapy.

Focus Areas

Surgical robotics Urology Benign Prostatic Hyperplasia (BPH) treatment Aquablation therapy AI-enabled robotic systems Prostate cancer (investigational)

Business Intelligence

TechnologyAQUABEAM Robotic System, HYDROS Robotic System, Aquablation therapy, real-time ultrasound imaging, AI-powered treatment planning (FirstAssist AI™), robotic resection, heat-free waterjet ablation

What Physicians Need to Know

Specialization
PROCEPT BioRobotics specializes in surgical robotics for urology, with a primary focus on treating Benign Prostatic Hyperplasia (BPH) using Aquablation therapy. They are also investigating the use of Aquablation therapy for prostate cancer.
Key Differentiators
Their core differentiator is Aquablation therapy, which utilizes a heat-free, image-guided, robotic-assisted waterjet to remove prostate tissue. This approach aims to provide durable symptom relief for BPH while preserving sexual and urinary function, independent of prostate size, shape, or surgeon experience.
Technology Stack
PROCEPT BioRobotics' technology stack includes the AquaBeam® Robotic System and the next-generation HYDROS® Robotic System. The HYDROS system is an AI-enabled robotic platform that leverages AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning for personalized, anatomy-specific therapy with robotic precision.
BPH Treatment (Aquablation Therapy)
Aquablation therapy is the first and only image-guided, robotic-assisted, heat-free waterjet treatment for BPH. It offers precise and rapid removal of prostate tissue with advanced real-time image guidance and personalized treatment planning. Clinical studies have shown long-lasting symptom relief with low rates of irreversible complications, including high rates of ejaculatory function preservation and continence.
AI-Enabled Robotic Systems
The HYDROS Robotic System is the first AI-enabled robotic platform specifically designed for BPH treatment with Aquablation therapy. It uses AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning to enable surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility.
Prostate Cancer (Investigational)
PROCEPT BioRobotics has received FDA Investigational Device Exemption (IDE) approval to investigate the safety and efficacy of Aquablation therapy for prostate cancer. They are conducting the WATER IV PCa trial, a randomized study comparing Aquablation therapy to radical prostatectomy for localized prostate cancer, with a focus on harm reduction and quality-of-life outcomes.
Physician Tip

For physicians, PROCEPT BioRobotics' Aquablation therapy offers a differentiated approach to BPH treatment, emphasizing precise, heat-free tissue removal with robotic assistance and real-time imaging. This can lead to consistent clinical outcomes and a reduced risk of complications like erectile dysfunction and incontinence, which are critical concerns for patients. The AI-enabled HYDROS system further enhances personalized treatment planning and reproducibility. The ongoing prostate cancer trials suggest a potential future expansion of Aquablation's utility, offering a less invasive alternative to traditional surgery. Reimbursement for Aquablation therapy is widespread, including Medicare and many commercial insurance plans, though prior authorization may be required for private insurers. The European Association of Urology (EAU) guidelines strongly recommend Aquablation therapy as an alternative to TURP for men with moderate-to-severe urinary symptoms due to BPH, especially for those interested in preserving ejaculatory function.

PROCEPT BioRobotics' systems, such as the AquaBeam and HYDROS, are integrated platforms combining imaging, robotics, fluidics, and software for a complete procedural solution. The HYDROS system specifically leverages AI for real-time ultrasound guidance and robotic-assisted treatment planning. The company's strategy focuses on maintaining clinical differentiation at the procedure level and improving usability and workflow. Their products combine specialized capital equipment with sterile single-use procedure components, indicating a closed system approach with dependence on their proprietary consumables.

Products by Procept Biorobotics

3 products in the directory

HYDROS Handpiece
PROCEPT BioRobotics
Surgical AI
The HYDROS Handpiece is a single-use component of Procept Biorobotics' HYDROS Robotic System, an AI-powered surgical platform for Aquablation therapy, treating benign prostatic hyperplasia (BPH) with precision and heat-free waterjet resection.
HYDROS TRUS Probe
PROCEPT BioRobotics
Radiology & Imaging AI
The HYDROS Robotic System is the next-generation, AI-powered platform for Aquablation therapy, offering a minimally invasive, robotic-assisted waterjet treatment for benign prostatic hyperplasia (BPH) that aims to provide durable symptom relief while preserving sexual function and continence.
HYDROS Robotic System
PROCEPT BioRobotics
Surgical AI
The HYDROS Robotic System by Procept Biorobotics is an AI-powered surgical robot for Aquablation therapy, treating benign prostatic hyperplasia (BPH) with advanced image guidance and robotic precision to preserve sexual function and continence.

Videos

News, demos, and interviews about Procept Biorobotics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Procept Biorobotics →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Procept BioRobotics' Aquablation therapy is specifically designed to treat Benign Prostatic Hyperplasia (BPH) using a heat-free, robotically controlled waterjet. It offers a minimally invasive alternative to traditional surgical interventions like TURP, aiming for comparable efficacy with potentially lower rates of sexual side effects and incontinence.
The AquaBeam Robotic System utilizes advanced imaging and AI-enabled robotic technology to provide precise, individualized Aquablation therapy for BPH. Its key advantages include real-time prostate mapping, autonomous execution of the treatment plan, and the ability to remove prostatic tissue with high accuracy, which can lead to consistent and reproducible outcomes.
Currently, Procept BioRobotics' primary focus and FDA clearance for the AquaBeam Robotic System are for the treatment of BPH. While the precision of their robotic platform may hold potential for other urological applications, any involvement in prostate cancer treatment would be investigational and would require separate clinical trials and regulatory approvals.
Procept BioRobotics provides comprehensive training programs for surgeons and clinical staff to ensure proficiency in using the AquaBeam Robotic System. They also offer ongoing technical support, maintenance services, and clinical support to optimize system performance and assist healthcare providers with patient selection and post-operative care.
The pricing structure for the AquaBeam Robotic System involves capital acquisition or leasing options, along with per-procedure costs for disposable components. Procept BioRobotics provides support and resources to healthcare facilities regarding reimbursement codes, economic models, and strategies to navigate financial considerations for integrating Aquablation therapy into their practice.
Procept BioRobotics adheres to stringent medical device regulations and patient safety standards, holding necessary clearances from regulatory bodies such as the FDA. They maintain a robust quality management system, conduct rigorous testing, and continuously monitor post-market surveillance data to ensure the safety and efficacy of their AquaBeam Robotic System.
Aquablation therapy for BPH is supported by several clinical studies demonstrating its efficacy in improving urinary symptoms and flow rates, with durable results out to five years. Published data also highlight its favorable safety profile, particularly concerning the low rates of de novo erectile dysfunction and ejaculatory dysfunction compared to traditional surgical options.

Related Companies

Radin Health offers a comprehensive suite of AI-powered, cloud-based solutions designed to enhance operational efficiency across all stages of the radiology workflow. Their platform integrates a Radiology Information System (RIS), Picture Archiving and Communication System (PACS), AI-driven Dictation, and RADIN SELECT for workflow management. These solutions aim to improve efficiency and productivity for administrators, medical […]

Spectrum Dynamics Medical is a pioneering medical device company focused on transforming nuclear medicine from analog to digital technology. They specialize in developing high-definition, solid-state based nuclear imaging technology, including digital SPECT (Single Photon Emission Computed Tomography) and SPECT/CT systems. Their products aim to meet the clinical needs and workflow demands of diagnostic imaging departments […]

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]

Siemens Healthineers is a leading global medical technology company that pioneers breakthroughs in healthcare. The company focuses on medical technology and diagnostics, offering a wide range of products including imaging systems, laboratory diagnostics, and advanced therapies. Their innovations aim to improve patient outcomes and make healthcare more accessible and sustainable. Siemens Healthineers has a strong […]

Samsung Medison Co. is a global medical equipment company specializing in diagnostic imaging devices, particularly ultrasound systems. Established in 1985, the company has become the largest manufacturer of ultrasound systems in Korea. Samsung Medison integrates advanced technologies, including information technology, video signal processing, semiconductors, and communication, into its medical equipment. This integration enables the development […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.